Duchenne muscular dystrophy

TORONTO, July 8, 2026 Satellos Bioscience Inc. announced encouraging six-month interim data from its ongoing Phase 2 TRAILHEAD clinical...

AACHEN, Germany, July 8, 2026 Grünenthal has announced that the U.S. Food and Drug Administration (FDA) has granted both...

Pratteln, Switzerland, July 1, 2026 Santhera Pharmaceuticals announced positive topline findings from a Phase 1 clinical study of AGAMREE®...

KYOTO, Japan, June 26, 2026 Nippon Shinyaku Co., Ltd. announced it has entered into an option agreement with Elixirgen...

SAN DIEGO, June 26, 2026 Capricor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has scheduled a...

NEWPORT BEACH, Calif., May 20, 2026 CureDuchenne announced a new partnership expansion with Tevard Biosciences to accelerate development of...

SEATTLE, May 20, 2026 Atossa Therapeutics announced that a new scientific manuscript exploring the utrophin-modulation potential of (Z)-endoxifen in...

PHILADELPHIA, May 14, 2026 GEMMA Biotherapeutics (GEMMABio) unveiled its new Duchenne muscular dystrophy (DMD) gene therapy program and presented...

BOULDER, Colo., May 7, 2026 Edgewise Therapeutics reported first quarter 2026 financial results while highlighting major progress across its...

PRATTELN, Switzerland, April 27, 2026 Santhera Pharmaceuticals has achieved a significant regulatory milestone with the European Medicines Agency’s (EMA)...